SCHEMBL8312967

SCHEMBL8312967

NS(=O)(=O)c1ccc2cccnc2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.56
LOXL2 Q9Y4K0 2/20 0.53
ALDH1A1 P00352 3/20 0.50
MEN1 O00255 1/20 0.50
CASP1 P29466 1/20 0.50
CASP7 P55210 1/20 0.50
KMT2A Q03164 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2C19 P33261 1/20 0.50
HTT P42858 1/20 0.50
NR4A2 P43354 1/20 0.50
TDP1 Q9NUW8 1/20 0.49
CA9 Q16790 6/20 0.48
CA12 O43570 4/20 0.48
CA1 P00915 6/20 0.48
CA2 P00918 6/20 0.48
MAPK1 P28482 1/20 0.46
PLG P00747 1/20 0.44
PLAU P00749 1/20 0.44
PLAT P00750 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7816978 0.86 LMNA (0.56) LMNAALDH1A1MEN1CASP1KMT2A
SCHEMBL25365468 0.84 ALDH1A1 (0.52) LMNALOXL2ALDH1A1MEN1CASP1
SCHEMBL28077282 0.83 CA2 (0.56) MEN1KMT2ACYP1A2CA9CA12
SCHEMBL19692951 0.82 NR4A2 (0.55) LMNALOXL2ALDH1A1MEN1CASP1
SCHEMBL11679834 0.82 HTT (0.55) LMNALOXL2ALDH1A1MEN1CASP1
SCHEMBL12831150 0.82 ALDH1A1 (0.55) LMNALOXL2ALDH1A1MEN1CASP1
SCHEMBL4627734 0.82 ALDH1A1 (0.55) LMNALOXL2ALDH1A1MEN1CASP1
SCHEMBL11681712 0.81 LOXL2 (0.50) LMNALOXL2ALDH1A1MEN1CASP1
Hydrochloric Acid SCHEMBL28291893 0.81 ALDH1A1 (0.54) LMNALOXL2ALDH1A1MEN1CASP1
SCHEMBL4267187 0.79 NAMPT (0.56) LOXL2ALDH1A1MEN1CASP1CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12247004-B2 2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use Oxford Drug Design Limited (GB) 2025-03-11 US disclosed
CN-114846000-B 2-Amino-N- (amino-oxo-aryl-lambda 6-sulfinyl) acetamide compounds and therapeutic uses thereof 牛津药物设计有限公司 2025-01-03 CN disclosed
EP-4313308-A1 TEAD INHIBITORS AND USES THEREOF Cedilla Therapeutics, Inc. (US) 2024-02-07 EP disclosed
US-20230114875-A1 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE Oxford Drug Design Limited (GB) 2023-04-13 US disclosed
EP-4077289-A1 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE Oxford Drug Design Limited (GB) 2022-10-26 EP disclosed
WO-2022204452-A1 TEAD INHIBITORS AND USES THEREOF CEDILLA THERAPEUTICS, INC. (US) 2022-09-29 WO disclosed
CN-114846000-A 2-amino-N- (amino-oxo-aryl- λ 6-thioalkyl) acetamide compounds and therapeutic uses thereof 牛津药物设计有限公司 2022-08-02 CN disclosed
WO-2021123237-A1 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE Oxford Drug Design Limited (GB) 2021-06-24 WO disclosed
WO-2021123237-A1 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE Oxford Drug Design Limited (GB) 2021-06-24 WO disclosed
WO-2014201173-A1 BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS AMGEN INC. (US) 2014-12-18 WO disclosed
CN-103214473-A Dibenzo[b,f][1,4]oxazapine compounds ARYX THERAPEUTICS INC 2013-07-24 CN disclosed
EP-0927164-A1 8-HYDROXY-7-SUBSTITUTED QUINOLINES AS ANTI-VIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 1999-07-07 EP disclosed
WO-1998011073-A1 8-HYDROXY-7-SUBSTITUTED QUINOLINES AS ANTI-VIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 1998-03-19 WO disclosed
US-4617382-A PRINTING; DYEING; SILK, LEATHER, WOOL AND POLYAMIDES CIBA-GEIGY CORPORATION (US) 1986-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12247004-B2 2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use AARS1, ASNS, GARS1 LMNA 1968/4885LOXL2 1408/4885ALDH1A1 2000/4885
US-20230114875-A1 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE AARS1, ASNS, GARS1 LMNA 1968/4885LOXL2 1408/4885ALDH1A1 2000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.